This retrospective analysis evaluates progression-free survival in patients using CDK4/6 inhibitors, implying support for current treatment standards.
Key Points
This study aims to evaluate the effectiveness of first-line CDK4/6 inhibitors in HR+/HER2− metastatic breast cancer by analyzing progression-free survival and predictors of early progression.
Conducted a retrospective analysis of 82 patients treated at a tertiary cancer center.
Compared outcomes between patients receiving first-line CDK4/6 inhibitors and those on non-CDK therapies.
Estimated progression-free survival using Kaplan-Meier methods.
Performed subgroup analyses and logistic regression for predictors of short progression-free survival.
Median progression-free survival was 22.2 months, with greater PFS in de novo cases compared to recurrent cases.
Visceral metastases were linked to shorter PFS, with 61% of CDK4/6-treated patients affected.
No significant difference in PFS was found between the two CDK4/6 inhibitors, palbociclib and abemaciclib.
The overall survival data was immature due to low event rates, with only 13.4% of patients experiencing death events.